Gevokizumab information

Gevokizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	Interleukin 1β
Clinical data
ATC code	None;
Identifiers
CAS Number	1129435-60-4 ;
ChemSpider	None;
UNII	QX3JU54GYQ;
KEGG	D09911;
Chemical and physical data
Formula	C6442H9962N1710O2010S52
Molar mass	145193.64 g·mol−1
	(what is this?) (verify)

Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta),^[1] a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases.

On August 25, 2017, XOMA Corporation licensed the global commercial rights to gevokizumab to Novartis. Under the license agreement, Novartis will have worldwide rights to gevokizumab, and will be solely responsible for the development and commercialization of antibodies and products containing antibodies arising from gevokizumab. XOMA received an approximately $16 million upfront payment, and Novartis repaid in its entirety the approximately €12 million of debt owed by XOMA to Les Laboratoires Servier. XOMA is eligible to receive up to $438 million in development, regulatory and commercial milestones plus tiered high-single to mid-double-digit royalties on net sales of gevokizumab.

^ Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, et al. (December 2016). "Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial". American Journal of Ophthalmology. 172: 104–110. doi:10.1016/j.ajo.2016.09.017. PMC 5121021. PMID 27663070.

[1] Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, et al. (December 2016). "Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial". American Journal of Ophthalmology. 172: 104–110. doi:10.1016/j.ajo.2016.09.017. PMC 5121021. PMID 27663070.

Gevokizumab information

and 26 Related for: Gevokizumab information

Gevokizumab

Dupilumab

Secukinumab

Ustekinumab

Tocilizumab

Guselkumab

CD4

Ixekizumab

Anakinra

Benralizumab

Interleukin 12

Theralizumab

Interleukin 6

Interleukin 1 beta

Interleukin 23

Interleukin 23 subunit alpha

Interleukin

Interleukin 4

Interleukin 2

Interleukin 17

Mepolizumab

Daclizumab

Interleukin 8

Interleukin 5

Basiliximab

Canakinumab